1. Robotic surgeryThe Jefferies analysts in their research note said that the expectation is for Medtronic’s minimally invasive therapies group to lead and perform better than the company’s average. A key to the group’s strategy is Medtronic’s new Hugo system that is meant to rival Intuitive Surgical’s da Vinci robots.
Martha said this week that the company has been able to manage through previously disclosed disruptions related to COVID-19 — as well as resolving software issue. The plan is to file for CE Mark and U.S. IDE approval in early 2021.
“We’re going to be a meaningful player in this market. Go big or go home,” Martha said.
In the orthopedics space, Medtronic is looking to add enhancements to its Mazor X spinal robotic system.